1. Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
- Author
-
Alexandre Reuben, Jacob Austin-Breneman, Zachary A. Cooper, and Jennifer A. Wargo
- Subjects
Male ,Cancer Research ,Antitumor immunity ,BRAF inhibitor ,Extramural ,medicine.medical_treatment ,Melanoma ,Immune effects ,Biology ,medicine.disease ,B7-H1 Antigen ,Targeted therapy ,Blockade ,Lymphocytes, Tumor-Infiltrating ,Oncology ,Immunology ,medicine ,Cancer research ,Humans ,Female ,Protein Kinase Inhibitors - Abstract
BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma. Clin Cancer Res; 21(14); 3102–4. ©2015 AACR. See related article by Kakavand et al., p. 3140
- Published
- 2015
- Full Text
- View/download PDF